GFAP and Alzheimer disease: In the current study, there was a profound glial reaction following the DS-AD NDEVs but not the control NDEVs injection—this glial reaction appeared to worsen with time, since densitometry showed increased Iba1 and GFAP staining in the 4-month compared to the 1-month groups.